The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 17, 2018

Filed:

Oct. 10, 2014
Applicants:

Universite Laval, Quebec, CA;

Hema-quebec, Saint-Laurent, CA;

University of Washington, Seattle, WA (US);

Inventors:

Eric Boilard, Quebec, CA;

Luc Boudreau, Dieppe, CA;

Louis Thibault, St-Augustin-de-Desmaures, CA;

Michael Herman Gelb, Seattle, WA (US);

Assignees:

Université Laval, Québec, CA;

Hérma-Québec, Saint-Laurent, CA;

University of Washington, Seattle, WA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/569 (2006.01); G01N 33/50 (2006.01); G01N 15/14 (2006.01); G01N 33/564 (2006.01); G01N 15/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/56966 (2013.01); G01N 15/14 (2013.01); G01N 33/502 (2013.01); G01N 33/5079 (2013.01); G01N 33/564 (2013.01); G01N 2015/0084 (2013.01); G01N 2015/1486 (2013.01); G01N 2500/10 (2013.01); G01N 2800/104 (2013.01); G01N 2800/222 (2013.01); G01N 2800/7095 (2013.01);
Abstract

The present disclosure highlights the relationship between extracellular mitochondrial components, optionally in combination with the secreted phospholipase A-IIA and/or an auto-antibody, and in vivo as well as in vitro and inflammatory reactions/conditions, especially those released as a result of the degradation of a platelet. The present disclosure provides methods for determining the presence of inflammatory mediators, for limiting inflammatory reactions/conditions, for the diagnosis inflammatory reactions/conditions, for screening therapeutics for the treatment and/or the alleviation of symptoms of inflammatory reactions/conditions based on the detection or modulation of the level of these extracellular mitochondrial components.


Find Patent Forward Citations

Loading…